Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 192 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Tachycardia, Ventricular Clear all

Conditions: Myocarditis, Premature Ventricular Contractions, Ventricular Tachycardia (VT)
Interventions: Not listed
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Inherited Cardiac Arrythmias, Long QT Syndrome (LQTS), Brugada Syndrome (BrS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Early Repolarization Syndrome (ERS), Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Normal Control Subjects
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Paroxysmal Supraventricular Tachycardia (PSVT)
Interventions: Not listed
Lead sponsor: Milestone Pharmaceuticals Inc.; Other
Eligibility: Not listed
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Tachycardia, Ventricular
Interventions: CyberHeart System; Device
Lead sponsor: Varian, a Siemens Healthineers Company; Industry
Eligibility: 60 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Ventricular Tachycardia, Ventricular Fibrillation, Sudden Cardiac Death, Heart Failure
Interventions: Not listed
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 1,778 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 72
States / cities: Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 69 more

Conditions: Ventricular Tachycardia, Arrhythmia
Interventions: 123I-metaiodobenzylguanidine; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Tachycardia, Ventricular, Catheter Ablation
Interventions: Antiarrhythmic drug; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Tachycardia, Ventricular
Interventions: Remifentanil; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Ventricular Tachycardia
Interventions: Dantrolene/Ryanodex, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Heart Failure, Ventricular Dysfunction, Sudden Death, Sudden Cardiac Arrest, Ventricular Tachycardia, Ventricular Fibrillation
Interventions: wearable defibrillator (LifeVest); Device
Lead sponsor: Zoll Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Paroxysmal Supraventricular Tachycardia (PSVT)
Interventions: Etripamil, Placebo; Drug
Lead sponsor: Milestone Pharmaceuticals Inc.; Other
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 26
States / cities: Phoenix, Arizona • Sacramento, California • Littleton, Colorado + 19 more

Conditions: Sudden Cardiac Death
Interventions: Electrophysiology study (EPS), Standard Care, Cardiac Magnetic Resonance (CMR); Procedure · Other
Lead sponsor: Western Sydney Local Health District; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1,058 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ventricular Tachycardia
Interventions: Magnetic Stimulation; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ventricular Tachycardia
Interventions: Not listed
Lead sponsor: Mid and South Essex NHS Foundation Trust; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ventricular Tachycardia
Interventions: amiodarone, sotalol, Biosense Webster's NAVI-STAR Thermo-Cool; Drug · Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Baltimore, Maryland • Durham, North Carolina • Columbus, Ohio + 2 more

Conditions: Ventricular Tachycardia
Interventions: Versed, Fentanyl, Propofol, Sevoflurane; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hyperkalemia
Interventions: Sodium Zirconium Cyclosilicate (SZC), SZC Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 2,690 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 57
States / cities: Huntsville, Alabama • Mesa, Arizona • Bakersfield, California + 47 more

Conditions: Ventricular Tachycardia, Ischemic Cardiomyopathy
Interventions: Ablation-index guided ventricular tachycardia ablation, Ventricular tachycardia ablation with no AI-guidance; Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 2 more

Conditions: Ventricular Tachycardia
Interventions: TcMS; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Long QT Syndrome
Interventions: Testosterone, Progesterone, Placebo, Ibutilide; Drug
Lead sponsor: Indiana University; Other
Eligibility: 65 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Tachycardia, Ventricular
Interventions: Bispectral index monitoring, Ramsey Sedation Scale; Device · Other
Lead sponsor: Baystate Medical Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Ventricular Arrhythmia
Interventions: Eleclazine, Placebo to match eleclazine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 37
States / cities: Mesa, Arizona • Long Beach, California • Los Angeles, California + 32 more

Conditions: Ventricular Tachycardia
Interventions: Boston Scientific Vessix Renal Denervation System; Device
Lead sponsor: Vivek Reddy; Other
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: New York, New York • Austin, Texas

Conditions: Sustained VT
Interventions: cryoablation procedure; Device
Lead sponsor: Adagio Medical; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • San Francisco, California • Baltimore, Maryland + 9 more

Search by objective public record fields.

Myocarditis Causing Premature Ventricular Contractions:Insights From the MAVERIC Registry

Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias

The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.

CyberHeart's Cardiac Arrhythmia Ablation Treatment: Patients With Refractory Ventricular Tachycardia/Fibrillation

DF4 Connector System Post-Approval Study

Imaging With a Radio Tracer to Guide VT Ablations

Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation

Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia

A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.

Study of the Wearable Defibrillator in Heart-Failure Patients

Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)

Randomized Assessment of TcMS for VT Storm

Outcomes of Functional Substrate Mapping of Ventricular Tachycardia

Pilot Study of Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator

Inducibility and Stability of Ventricular Tachycardia Inpatients Undergoing VT Ablation Under General Anesthesia

Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy

TcMS to Treat Ventricular Tachycardia

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

Bispectral Index Monitoring During Testing in the Electrophysiology Lab

Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator

REnal SympathetiC Denervation to sUpprEss Tachyarrhythmias in ICD Recipients

Cryoablation for Monomorphic Ventricular Tachycardia